Business
CSL ‘cautious’ on profit outlook even after vaccines boosted half-year results – Sydney Morning Herald
Australia’s local maker of AstraZeneca Oxford’s COVID-19 jabs beat market expectations as sales of its seasonal influenza vaccines soared in the face of COVID-19,…
The full-year result will be heavily skewed to the first half, he told analysts. The impacts of COVID, both positive and negative, add a pretty heavy layer of complexity and uncertainty to our earnings profile until we get through this pandemic.
CSL maintained its previous earnings guidance, predicting profits of between $2.17 and $2.27 billion for the 2021 financial year. Asked why the $131 billion biotech wasnt increasing its forecasts, Mr Perreault highlighted that because of the seasonal nature…
-
General23 hours agoAlgal bloom ‘disaster’ prompts royal commission call as impact spreads to mussel farms
-
Noosa News22 hours agoE-bikes shouldn’t be banned. The illegal ones are already illegal
-
General19 hours agoChina was the big disruptor in our region. Now the US is determined to take that title
-
General19 hours agoSpaceX to invest $3 billion in Musk’s xAI startup